Effect Mechanism Investigation of a Non-invasive Stimulation Device for Rapid Alleviation of Parkinson's Disease Symptoms
Effect Mechanism of a Non-invasive Stimulation Device for Rapid Alleviation of Parkinson's Disease Symptoms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
İstanbul, Turkey
- Koc University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Parkinson's Disease
- H&Y Stage >= 2
- Existing bradykinesia symptoms
- Existence of one of the symptoms below
- Resting Tremor
- Rigidity
- Walking disorder
Exclusion Criteria:
- Cardiac Pacemaker
- Psychiatric diagnosis
- Irregular heart/respiration rate
- Pregnancy
- Alcohol consumption
- Cardiovascular disease history
- Wearing an electro-active prosthesis
- Brain surgery history
- Ongoing TENS/PENS therapy-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active Stimulation
Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
|
Percutaneous electrical nerve stimulation
|
|
Other: Dry Needling
Acupuncture needles will be inserted into the auricular zones for 20 minutes.
However, no electrical stimulation will be given
|
Percutaneous nerve stimulation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
fMRI - Activation level comparison of the motor and supplementary cortex
Time Frame: Baseline and PostStim (right after the stimulation is terminated)
|
Baseline and PostStim (right after the stimulation is terminated)
|
|
fMRI - Activation level comparison of the subthalamic nucleus (STN) and basal ganglia including pedunculopontine nucleus (PPN)
Time Frame: Baseline and PostStim (right after the stimulation is terminated)
|
Baseline and PostStim (right after the stimulation is terminated)
|
|
fMRI - STN, PPN and cortical connectivity alterations
Time Frame: Baseline and PostStim (right after the stimulation is terminated)
|
Baseline and PostStim (right after the stimulation is terminated)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Yusuf O Cakmak, Phd, MD, Otago University
- Study Director: Burak Ozsoy, PhD, Inventram
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Par-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
NCT07148700RecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s Disease
-
NCT07217054RecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s Disease
-
NCT06680830RecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)
-
NCT07554833Not yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s Disease
-
NCT07312110RecruitingParkinson Disease (PD) | Parkinson s Disease
-
NCT07630792Not yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
NCT07204652RecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)
-
NCT06705517RecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)
-
NCT02511015CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
-
NCT07567794Not yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons Disease
Clinical Trials on Electrical Stimulation
-
NCT05198466CompletedCOVID-19 | Muscle Weakness | Muscle Atrophy
-
NCT04685213CompletedCovid19 | Muscle Weakness | Muscle Atrophy
-
NCT05672290Not yet recruiting
-
NCT03821675CompletedDiabetes | Peripheral Arterial Disease | Diabetic Foot Ulcer | Peripheral Neuropathy
-
NCT07433218Not yet recruitingHypotension | Anesthesia
-
NCT00369668CompletedHemiplegia | Cerebrovascular Accident
-
NCT03815994SuspendedRehabilitation | Critical Care
-
NCT01886430Completed
-
NCT07491341Completed